Does the media refer more to ACAD or ADMA?

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.59 beat ACADIA Pharmaceuticals' score of -0.16 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADMA or ALLO?

In the previous week, ADMA Biologics and ADMA Biologics both had 3 articles in the media. ADMA Biologics' average media sentiment score of 0.59 beat Allogene Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, ADMA or PCVX?

ADMA Biologics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $510.17M 4.55 $146.93M $0.70 14.80 Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is ADMA or PCVX more profitable?

ADMA Biologics has a net margin of 32.98% compared to Vaxcyte's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.98% 40.17% 26.97% Vaxcyte N/A -37.56% -33.62%

Does the media favor ADMA or PCVX?

In the previous week, Vaxcyte had 49 more articles in the media than ADMA Biologics. MarketBeat recorded 52 mentions for Vaxcyte and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.59 beat Vaxcyte's score of 0.47 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 16 Very Positive mention(s) 10 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ADMA or APGE?

In the previous week, ADMA Biologics had 2 more articles in the media than Apogee Therapeutics. MarketBeat recorded 3 mentions for ADMA Biologics and 1 mentions for Apogee Therapeutics. ADMA Biologics' average media sentiment score of 0.59 beat Apogee Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ADMA or TGTX?

TG Therapeutics has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $510.17M 4.55 $146.93M $0.70 14.80 TG Therapeutics $616.29M 13.75 $447.18M $2.74 20.21

Does the media prefer ADMA or TGTX?

In the previous week, TG Therapeutics had 7 more articles in the media than ADMA Biologics. MarketBeat recorded 10 mentions for TG Therapeutics and 3 mentions for ADMA Biologics. TG Therapeutics' average media sentiment score of 0.68 beat ADMA Biologics' score of 0.59 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ADMA Biologics (ADMA) Competitors

$10.36 +0.03 (+0.29%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.28 -0.07 (-0.72%)

As of 10/9/2026 07:30 PM Eastern

Compare

ADMA vs. ACAD, ALLO, PCVX, APGE, and TGTX

Should you buy ADMA Biologics stock or one of its competitors? ADMA Biologics's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Allogene Therapeutics (ALLO), Vaxcyte (PCVX), Apogee Therapeutics (APGE), and TG Therapeutics (TGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.59 beat ACADIA Pharmaceuticals' score of -0.16 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals presently has a consensus target price of $32.71, indicating a potential upside of 65.37%. ADMA Biologics has a consensus target price of $18.67, indicating a potential upside of 80.18%. Given ADMA Biologics' higher possible upside, analysts plainly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.18	$391M	$2.22	8.91
ADMA Biologics	$510.17M	4.55	$146.93M	$0.70	14.80

ACADIA Pharmaceuticals has a net margin of 33.42% compared to ADMA Biologics' net margin of 32.98%. ADMA Biologics' return on equity of 40.17% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
ADMA Biologics	32.98%	40.17%	26.97%

Summary

ACADIA Pharmaceuticals beats ADMA Biologics on 10 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Allogene Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

In the previous week, ADMA Biologics and ADMA Biologics both had 3 articles in the media. ADMA Biologics' average media sentiment score of 0.59 beat Allogene Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

ADMA Biologics currently has a consensus target price of $18.67, suggesting a potential upside of 80.18%. Allogene Therapeutics has a consensus target price of $8.30, suggesting a potential upside of 468.49%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

ADMA Biologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.55	$146.93M	$0.70	14.80
Allogene Therapeutics	$20K	25,220.77	-$190.89M	-$0.67	N/A

ADMA Biologics has a net margin of 32.98% compared to Allogene Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Allogene Therapeutics	N/A	-50.04%	-36.74%

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ADMA Biologics beats Allogene Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Vaxcyte?

ADMA Biologics (NASDAQ:ADMA) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Vaxcyte had 49 more articles in the media than ADMA Biologics. MarketBeat recorded 52 mentions for Vaxcyte and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.59 beat Vaxcyte's score of 0.47 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	16 Very Positive mention(s)	10 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.55	$146.93M	$0.70	14.80
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

ADMA Biologics has a net margin of 32.98% compared to Vaxcyte's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Vaxcyte	N/A	-37.56%	-33.62%

ADMA Biologics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

ADMA Biologics presently has a consensus price target of $18.67, indicating a potential upside of 80.18%. Vaxcyte has a consensus price target of $108.60, indicating a potential upside of 52.14%. Given ADMA Biologics' higher possible upside, equities research analysts clearly believe ADMA Biologics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

ADMA Biologics beats Vaxcyte on 10 of the 15 factors compared between the two stocks.

How does ADMA Biologics compare to Apogee Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

ADMA Biologics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.55	$146.93M	$0.70	14.80
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

ADMA Biologics has a net margin of 32.98% compared to Apogee Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Apogee Therapeutics	N/A	-29.88%	-28.08%

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ADMA Biologics had 2 more articles in the media than Apogee Therapeutics. MarketBeat recorded 3 mentions for ADMA Biologics and 1 mentions for Apogee Therapeutics. ADMA Biologics' average media sentiment score of 0.59 beat Apogee Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics presently has a consensus target price of $18.67, suggesting a potential upside of 80.18%. Apogee Therapeutics has a consensus target price of $126.77, suggesting a potential downside of 6.14%. Given ADMA Biologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ADMA Biologics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

Summary

ADMA Biologics beats Apogee Therapeutics on 13 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to TG Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

ADMA Biologics currently has a consensus target price of $18.67, indicating a potential upside of 80.18%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 13.78%. Given ADMA Biologics' higher possible upside, equities research analysts clearly believe ADMA Biologics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

TG Therapeutics has a net margin of 55.22% compared to ADMA Biologics' net margin of 32.98%. TG Therapeutics' return on equity of 73.49% beat ADMA Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
TG Therapeutics	55.22%	73.49%	34.14%

In the previous week, TG Therapeutics had 7 more articles in the media than ADMA Biologics. MarketBeat recorded 10 mentions for TG Therapeutics and 3 mentions for ADMA Biologics. TG Therapeutics' average media sentiment score of 0.68 beat ADMA Biologics' score of 0.59 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.55	$146.93M	$0.70	14.80
TG Therapeutics	$616.29M	13.75	$447.18M	$2.74	20.21

ADMA Biologics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

TG Therapeutics beats ADMA Biologics on 14 of the 16 factors compared between the two stocks.

Get ADMA Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADMA vs. The Competition

Export

Metric	ADMA Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.31B	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	14.80	13.42	274.15	26.16
Price / Sales	4.55	1,234.32	589.97	94.50
Price / Cash	15.79	116.56	76.38	53.09
Price / Book	5.15	17.17	11.21	6.34
Net Income	$146.93M	-$22.69M	$3.50B	$381.90M
7 Day Performance	6.58%	-1.33%	-0.90%	-1.41%
1 Month Performance	10.33%	-8.44%	-4.44%	-3.48%
1 Year Performance	-28.75%	14.02%	6.96%	1.16%

ADMA Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADMA ADMA Biologics	4.0342 of 5 stars	$10.36 +0.3%	$18.67 +80.2%	-29.7%	$2.31B	$510.17M	14.80	647
ACAD ACADIA Pharmaceuticals	4.6546 of 5 stars	$20.11 +0.8%	$32.76 +62.9%	-4.1%	$3.44B	$1.14B	9.06	798	Analyst Forecast
ALLO Allogene Therapeutics	2.4432 of 5 stars	$1.50 flat	$8.30 +453.3%	-3.3%	$518.24M	$20K	N/A	152	Analyst Downgrade
PCVX Vaxcyte	2.9433 of 5 stars	$73.82 +30.7%	$108.60 +47.1%	+70.0%	$8.40B	N/A	N/A	507	Trending News Insider Trade Options Volume High Trading Volume
APGE Apogee Therapeutics	0.9256 of 5 stars	$135.07 flat	$126.77 -6.1%	N/A	$8.40B	N/A	N/A	91

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADMA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, PCVX, APGE, and TGTX

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Summary

How does ADMA Biologics compare to Vaxcyte?

Summary

How does ADMA Biologics compare to Apogee Therapeutics?

Summary

How does ADMA Biologics compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, PCVX, APGE, and TGTX

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Do insiders and institutionals hold more shares of ACAD or ADMA?

Which has more risk and volatility, ACAD or ADMA?

Does the media refer more to ACAD or ADMA?

Do analysts prefer ACAD or ADMA?

Which has higher valuation & earnings, ACAD or ADMA?

Is ACAD or ADMA more profitable?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Does the media prefer ADMA or ALLO?

Which has more volatility and risk, ADMA or ALLO?

Do analysts recommend ADMA or ALLO?

Which has better earnings and valuation, ADMA or ALLO?

Is ADMA or ALLO more profitable?

Do institutionals and insiders hold more shares of ADMA or ALLO?

Summary

How does ADMA Biologics compare to Vaxcyte?

Do institutionals and insiders have more ownership in ADMA or PCVX?

Does the media favor ADMA or PCVX?

Which has stronger valuation and earnings, ADMA or PCVX?

Is ADMA or PCVX more profitable?

Which has more risk and volatility, ADMA or PCVX?

Do analysts recommend ADMA or PCVX?

Summary

How does ADMA Biologics compare to Apogee Therapeutics?

Which has more volatility and risk, ADMA or APGE?

Which has higher earnings and valuation, ADMA or APGE?

Is ADMA or APGE more profitable?

Do insiders and institutionals believe in ADMA or APGE?

Does the media prefer ADMA or APGE?

Do analysts recommend ADMA or APGE?

Summary

How does ADMA Biologics compare to TG Therapeutics?

Do analysts recommend ADMA or TGTX?

Is ADMA or TGTX more profitable?

Does the media prefer ADMA or TGTX?

Which has preferable earnings & valuation, ADMA or TGTX?

Which has more risk & volatility, ADMA or TGTX?

Do institutionals & insiders have more ownership in ADMA or TGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools